Top Markets
Coin of the day
AIkido Pharma Inc. AIkido Pharma Inc.

AIkido Pharma Inc.

AIKI
Rangering i aksjer #29992
AIkido Pharma Inc., established in 1967 and headquartered in New York, New... AIkido Pharma Inc., established in 1967 and headquartered in New York, New York, is a biotechnology company primarily engaged in pioneering small-molecule anti-cancer treatments. The firm, which operated as Spherix Incorporated until its rebranding in March 2021, possesses a robust therapeutic pipeline addressing various malignancies, including prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. Key drug candidates in its development portfolio include DHA-dFdC, targeting pancreatic cancer, and KPC34, a small molecule designed for the treatment of both AML and acute lymphoblastic leukemia. Furthermore, AIkido Pharma Inc. is advancing an antiviral platform engineered to hinder the proliferation of numerous viruses, such as the influenza virus, Ebolavirus, Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. The company holds strategic license agreements with several academic and research institutions, including the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences.
Aksjekurs
$3.56
Sist synkronisert: 2022-12-21
Markedsverdi
$18.70M
Endring (1 dag)
0.28%
Endring (1 år)
0.00%
Land
US
Handel AIkido Pharma Inc. (AIKI)

Kategori

EPS for AIkido Pharma Inc. (AIKI)
EPS per 2026 TTM: 0
Ifølge de siste økonomiske rapportene og aksjekursen til AIkido Pharma Inc. er selskapets nåværende EPS (TTM) 0. Ved slutten av 2026 hadde selskapet en EPS på 0, lik EPS-en i 2026 som var 0.
EPS-historikk for AIkido Pharma Inc. fra 2026 til 2026
EPS ved slutten av hvert år
År EPS Endre
Ikke nok data for de angitte datoene.
EPS for lignende selskaper eller konkurrenter